Brain Drug Delivery Systems for Neurodegenerative Disorders

Author(s): E. Garbayo, E. Ansorena, M.J. Blanco-Prieto

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 12 , 2012

Become EABM
Become Reviewer


Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.

Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [2388 - 2402]
Pages: 15
DOI: 10.2174/138920112803341761
Price: $65

Article Metrics

PDF: 10